GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Short-Term Debt

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Short-Term Debt : $0.00 Mil (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Short-Term Debt?

CERo Therapeutics Holdings's Short-Term Debt for the quarter that ended in Dec. 2022 was $0.00 Mil.


CERo Therapeutics Holdings Short-Term Debt Historical Data

The historical data trend for CERo Therapeutics Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Short-Term Debt Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Short-Term Debt
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Short-Term Debt - -

CERo Therapeutics Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


CERo Therapeutics Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines